Capital Fund Management (CFM)’s VanEck Biotech ETF BBH Stock Holding History

Capital Fund Management (CFM)’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,600	Closed	-$433K	–	1977
2018 Q1	$433K	Sell	3,600 -1,800	-33%	-$226K	﹤0.01%	1499
2017 Q4	$673K	Buy	+5,400	New	+$690K	﹤0.01%	1351
2017 Q3	–	Sell	-3,800	Closed	-$477K	–	1512
2017 Q2	$477K	Buy	+3,800	New	+$458K	﹤0.01%	1136
2017 Q1	–	Sell	-8,800	Closed	-$947K	–	1457
2016 Q4	$947K	Buy	+8,800	New	+$957K	0.01%	1035

Other funds holding BBH

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Capital Fund Management (CFM)'s BBH Position: Q2 2018 in Review

Capital Fund Management (CFM) sold out of VanEck Biotech ETF (BBH) in Q2 2018, closing a stake of 3,600 shares — an estimated $433K sold.

Capital Fund Management (CFM) first reported a position in BBH in Q4 2016 and held it in 4 quarters. The position peaked at $947K in Q4 2016. 83 funds tracked by Wall St. Rank hold BBH as of Q2 2018.

Capital Fund Management (CFM) reported no remaining VanEck Biotech ETF position as of Q2 2018 after selling out during the quarter.
Capital Fund Management (CFM) sold 3,600 VanEck Biotech ETF shares in Q2 2018, an estimated $433K.
Capital Fund Management (CFM) first reported a position in VanEck Biotech ETF in Q4 2016 and held it in 4 quarters.
Capital Fund Management (CFM)'s VanEck Biotech ETF position peaked at $947K in Q4 2016.
83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2018.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2018, filed 14 Aug 2018.